Key facts
- Aplagon’s last known valuation is $16.0M (Apr 2021).
- It has raised $13.6M; the latest was Later Stage VC ($7.2M) in Feb 2025.
- Notable investors include European Innovation Council, Innovestor, Business Finland, Finnvera, University of Helsinki Endowment — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Aplagon
- ·The full record, as it builds
Funding rounds
No funding rounds for Aplagon are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aplagon
Developer of antithrombotic compounds designed to treat complications of vascular intervention-related blood vessel occlusions. The company's compounds are engaged in developing biological mimetics of heparin proteoglycan for the clinical management of vascular injury-related thrombotic occlusions and ischemic reperfusion injuries, enabling medical professionals to provide patients with effective antithrombotic medicines with safety advantages.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Founded
- 2009
- Employees
- 6
- Website
- aplagon.com/
- Ownership
- Privately Held (backing)
Aplagon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aplagon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aplagon in its N-PORT filings yet. We sweep new filings monthly.